BioNTech SE (BNTX) Non-Current Deffered Revenue (2018 - 2025)

BioNTech SE has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $102.4 million in Q4 2025.

• Quarterly Non-Current Deffered Revenue fell 47.62% year-over-year to $102.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $102.4 million (down 47.62% YoY) and the FY2025 annual result came in at $99.4 million, down 49.16% from the prior year.
• Non-Current Deffered Revenue fell to $102.4 million in Q4 2025 per BNTX's latest filing, from $195.6 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $428.8 million in Q4 2023 and troughed at $10.3 million in Q4 2021.
• A 5-year average of $157.3 million and a median of $102.4 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2023: Non-Current Deffered Revenue tumbled 87.99% in 2021, then soared 768.29% in 2023.
• Over 5 years, Non-Current Deffered Revenue stood at $10.3 million in 2021, then soared by 379.62% to $49.4 million in 2022, then jumped by 768.29% to $428.8 million in 2023, then plunged by 54.39% to $195.6 million in 2024, then plunged by 47.62% to $102.4 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $102.4 million, $195.6 million, and $428.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.